Eton Pharmaceuticals, Inc.

NASDAQ•ETON

CEO: Mr. Sean E. Brynjelsen

セクター: Healthcare

業種: Biotechnology

上場日: 2018-11-13

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

連絡先情報

21925 W. Field Parkway, Suite 235, Deer Park, IL, 60010-7278, United States

847-787-7361

www.etonpharma.com

時価総額

$510.07M

PER (TTM)

-76.5

17.5

配当利回り

52週高値

$23.00

52週安値

$11.09

52週レンジ

67%

順位56Top 81.7%

2.5

F-Score

改良版 Piotroski 分析

8年ファンダメンタル

弱い • 2.5 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$22.46M+117.54%

直近4四半期の推移

EPS

-$0.07-389.26%

直近4四半期の推移

フリーCF

$11.74M+297.76%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Month Revenue Surge Nine months total revenues hit $58.67M, marking a substantial 114.4% increase versus prior year period driven by product sales.

Gross Profit Expansion Nine months gross profit reached $29.64M, increasing 75.0% due to strong product sales and royalties growth.

Strong Operating Cash Flow Operating cash flow provided $22.08M cash over nine months, a major improvement from $1.73M provided previously.

Cash Position Solidified Cash and equivalents totaled $37.12M at period end, supporting short-term liquidity needs for the next twelve months.

リスク要因

Net Loss Widening Nine months net loss widened to $(6.08M) compared to $(3.23M) loss last year due to higher operating expenses.

Customer Concentration Exposure High customer concentration risk exists; AnovoRx accounted for 85.8% of net product revenues for the nine months.

ESPP Issuance Halted ESPP share issuance suspended for nine months 2025 due to failure filing required INCRELEX® financial statements.

Substantial Long-Term Debt Long-term debt stands at $27.59M, requiring quarterly principal payments starting May 2026, impacting future cash flow.

見通し

Advancing Late-Stage Pipeline Five late-stage candidates including ET-600 and Amglidia® are advancing development efforts to expand rare disease portfolio.

Liquidity Runway Confirmed Current cash plus product revenues expected sufficient to fund operations for at least the next twelve months period.

Increased R&D Investment R&D spending rose due to $2.16M NDA filing fee for ET-600 and increased ET-700/ET-800 project costs.

Evaluating Tax Disclosure Changes Evaluating impact of new FASB ASU 2023-09 regarding income tax disclosures, effective for annual periods beginning 2025.

同業比較

売上高 (TTM)

RIGL

$294.28M

+64.1%

ADCT

$81.36M

+14.9%

ETON

$70.32M

+102.8%

粗利益率 (最新四半期)

OCGN

1337.8%

+0.0pp

ALMS

100.0%

+0.0pp

BCYC

100.0%

+1705.8pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ALMS	$2.61B	-10.6	-75.5%	7.7%
CRVS	$1.34B	-82.7	-23.3%	1.3%
RAPT	$959.26M	-14.8	-61.8%	1.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

24.5%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

75%

キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年3月17日

EPS:$0.12

売上高:$20.58M

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし